1. DRAICmediates hnRNPA2B1 stability and m6A-modified IGF1Rinstability to inhibit tumor progression
- Author
-
Wen, Ya, Yang, Xiwang, Li, Yifei, Zhao, Xueqing, Ding, Ao, Song, Dalong, Duan, Liqiang, Cheng, Shuwen, Zhu, Xiaofeng, Peng, Bo, Chang, Xiaoli, Zhang, Chang, Yang, Facai, Cheng, Tianyou, Wang, He, Zhang, Yibi, Zhang, Tiantian, Zheng, Shizhong, Ren, Li, and Gao, Shan
- Abstract
Type 1 insulin-like growth factor receptor (IGF1R) plays an important role in cancer, however, posttranscriptional regulation such as N6-methyladenosine (m6A) of IGF1Rremains unclear. Here, we reveal a role for a lncRNA Downregulated RNA in Cancer(DRAIC)suppress tumor growth and metastasis in clear cell Renal Carcinoma (ccRCC). Mechanistically, DRAICphysically interacts with heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and enhances its protein stability by blocking E3 ligase F-box protein 11 (FBXO11)-mediated ubiquitination and proteasome-dependent degradation. Subsequently, hnRNPA2B1 destabilizes m6A modified-IGF1R, leading to inhibition of ccRCC progression. Moreover, four m6A modification sites are identified to be responsible for the mRNA degradation of IGF1R. Collectively, our findings reveal that DRAIC/hnRNPA2B1 axis regulates IGF1RmRNA stability in an m6A-dependent manner and highlights an important mechanism of IGF1R fate. These findings shed light on DRAIC/hnRNPA2B1/FBXO11/IGF1Raxis as potential therapeutic targets in ccRCC and build a link of molecular fate between m6A-modified RNA and ubiquitin-modified protein.
- Published
- 2024
- Full Text
- View/download PDF